Budget Impact Of Eltrombopag As First-Line Treatment For Severe Aplastic Anemia In The United States

BACKGROUND: Severe aplastic anemia (SAA) is a rare autoimmune condition resulting in low blood cell counts across lineages. Immunosuppressive therapy (IST) has demonstrated low response, toxicity, and risk of transformation. In a Phase I/II trial, the addition of eltrombopag to first-line IST increa...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremblay, Gabriel, Said, Qayyim, Roy, Anuja Nidumolu, Cai, Beilei, Ashton Garib, Shan, Hearnden, Jaclyn, Forsythe, Anna
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858800/
https://www.ncbi.nlm.nih.gov/pubmed/31814747
http://dx.doi.org/10.2147/CEOR.S226323

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6858800/
https://www.ncbi.nlm.nih.gov/pubmed/31814747
http://dx.doi.org/10.2147/CEOR.S226323

Ejemplares similares